Wenyong Tan

Southern Medical University

Prof. Dr. Wenyong Tan has been a clinical oncologist for more than 20 years, and he is the director of the Department of Oncology, Shenzhen Hospital of Southern Medical University. Dr. Tan He has been devoted to the radiotherapy and anti-cancer drugs therapy cancer diagnosis and treatment, especially focusing on lung cancer, breast cancer as well as head and neck cancer. He is also an active clinically translational researchers and mainly focus on the optimizing the cancer treatment strategies and minimizing the cancer therapy associated cardiac toxicities. Dr. Tan has published more than 50 academic papers in collaboration with co-authors and nine international academic meeting abstracts.

1books edited

1chapters authored

Latest work with IntechOpen by Wenyong Tan

Cardiotoxicity may be caused by radiotherapy and/or anticancer agents for many malignancies, adverse effects of some drugs in the context of medical intervention or heavy metal intake, especially during the anticancer therapy. This book intends to bring forward the recent development in toxicities from cancer treatment. It updates the possible mechanisms of cardiotoxicities of some anticancer agents and the suggested prevention and treatment strategies. This book contains many valuable contributions from the researchers in oncology and cardiology as well as the clinicians who are experts in this field.

Go to the book

Cardiotoxicity

Edited by Wenyong Tan

Chapters authored

By Wenyong Tan, Xianming Li and Yong Dai

Approximately 25–30% of patients with cancer undergo thoracic radiation therapy (RT). RT might inadvertently induce heart injury and result in various forms of radiation-related heart disease (RRHD). The main endpoints of RRHD include cardiac death from RT, clinical heart disease (congestive heart disease, ischemic heart disease, and myocardial infarction), and subclinical heart disease (cardiac perfusion defects). Advanced RT techniques, such as breath control, intensity-modulated RT, and image-guided RT, as well as limited target volume definition might spare or avoid cardiac doses and/or volume, which may translate into decreased incidence of RRHD. The total delivered radiation dose to cardiac implantable electronic devices was strongly recommended not to exceed 2 Gy. The treatment strategies of RRHD were based on the various recommended consensus of related heart diseases in cardiology. However, the standardized definitions of the cardiac structures, dose-volume limits during radiation planning design, the optimal dose-volume parameters, and the dose-volume effects of various cardiac substructures warrant further investigation. The recognition, prediction, prevention, and management of RRHD require close collaboration between oncologists and cardiologists.

Part of the book: Radiotherapy

Wenyong Tan

Latest work with IntechOpen by Wenyong Tan

Cardiotoxicity

Chapters authored

Related collaborators

Ryohei Sasaki

Hiroaki Akasaka

Tianyuan Wang

Viktoras Rudzianskas

Naritoshi Mukumoto

Ryuichi Yada

Yasuyuki Shimizu

Saki Osuga

Yuki Wakahara

Masao Nakayama

Your cart